

Philip R Dormitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502351/publications.pdf>

Version: 2024-02-01

69
papers

28,644
citations

46984

47
h-index

85498

71
g-index

80
all docs

80
docs citations

80
times ranked

33806
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
2	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
3	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. <i>Nature</i> , 2020, 586, 594-599.	13.7	1,520
4	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
5	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
6	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
7	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583
8	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.	15.2	562
9	Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.	13.9	528
10	Nonviral delivery of self-amplifying RNA vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 14604-14609.	3.3	498
11	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
12	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. <i>Science</i> , 2021, 371, 1152-1153.	6.0	485
13	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	13.9	431
14	Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14216-14221.	3.3	402
15	Near-atomic resolution using electron cryomicroscopy and single-particle reconstruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1867-1872.	3.3	347
16	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	13.9	346
17	SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 3198-3203.	1.6	328
18	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318

#	ARTICLE	IF	CITATIONS
19	The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. <i>EMBO Journal</i> , 2002, 21, 885-897.	3.5	305
20	A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines. <i>Molecular Therapy</i> , 2014, 22, 2118-2129.	3.7	255
21	Atomic model of an infectious rotavirus particle. <i>EMBO Journal</i> , 2011, 30, 408-416.	3.5	254
22	Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 9619-9624.	3.3	233
23	Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 264-269.	3.3	227
24	Structure of Rotavirus Outer-Layer Protein VP7 Bound with a Neutralizing Fab. <i>Science</i> , 2009, 324, 1444-1447.	6.0	216
25	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.	13.9	215
26	Nemaline Myopathy with Minicores Caused by Mutation of the CFL2 Gene Encoding the Skeletal Muscle Actin-Actin-Binding Protein, Cofilin-2. <i>American Journal of Human Genetics</i> , 2007, 80, 162-167.	2.6	213
27	Structural rearrangements in the membrane penetration protein of a non-enveloped virus. <i>Nature</i> , 2004, 430, 1053-1058.	13.7	200
28	Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics. <i>Science Translational Medicine</i> , 2013, 5, 185ra68.	5.8	164
29	Influenza vaccine immunology. <i>Immunological Reviews</i> , 2011, 239, 167-177.	2.8	146
30	Structure-based antigen design: a strategy for next generation vaccines. <i>Trends in Biotechnology</i> , 2008, 26, 659-667.	4.9	143
31	Molecular interactions in rotavirus assembly and uncoating seen by high-resolution cryo-EM. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10644-10648.	3.3	135
32	Self-Amplifying mRNA Vaccines. <i>Advances in Genetics</i> , 2015, 89, 179-233.	0.8	130
33	Conformational States of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Ectodomain. <i>Journal of Virology</i> , 2006, 80, 6794-6800.	1.5	120
34	Structural vaccinology starts to deliver. <i>Nature Reviews Microbiology</i> , 2012, 10, 807-813.	13.6	116
35	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. <i>Nature Medicine</i> , 2016, 22, 1465-1469.	15.2	104
36	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. <i>New England Journal of Medicine</i> , 2021, 385, 472-474.	13.9	93

#	ARTICLE	IF	CITATIONS
37	Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. <i>Nature Communications</i> , 2022, 13, 1536.	5.8	93
38	A Cell Cultureâ€‘Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults. <i>Science Translational Medicine</i> , 2014, 6, 234ra55.	5.8	81
39	Prefusion F Proteinâ€‘Based Respiratory Syncytial Virus Immunization in Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1615-1626.	13.9	78
40	High-Resolution Molecular and Antigen Structure of the VP8* Core of a Sialic Acid-Independent Human Rotavirus Strain. <i>Journal of Virology</i> , 2006, 80, 1513-1523.	1.5	77
41	The Status of Vaccine Development Against the Human Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2020, 221, S113-S122.	1.9	73
42	Influenza: Options to Improve Pandemic Preparation. <i>Science</i> , 2012, 336, 1531-1533.	6.0	71
43	Assembly of Highly Infectious Rotavirus Particles Recoated with Recombinant Outer Capsid Proteins. <i>Journal of Virology</i> , 2006, 80, 11293-11304.	1.5	70
44	Specificity and Affinity of Sialic Acid Binding by the Rhesus Rotavirus VP8* Core. <i>Journal of Virology</i> , 2002, 76, 10512-10517.	1.5	68
45	Generation of a parvovirus B19 vaccine candidate. <i>Vaccine</i> , 2013, 31, 3872-3878.	1.7	59
46	Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. <i>New England Journal of Medicine</i> , 2022, 386, 2377-2386.	13.9	54
47	A Rotavirus Spike Protein Conformational Intermediate Binds Lipid Bilayers. <i>Journal of Virology</i> , 2010, 84, 1764-1770.	1.5	50
48	New technologies for influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 45-58.	1.4	48
49	Proteolysis of Monomeric Recombinant Rotavirus VP4 Yields an Oligomeric VP5* Core. <i>Journal of Virology</i> , 2001, 75, 7339-7350.	1.5	46
50	Alternative intermolecular contacts underlie the rotavirus VP5* two- to three-fold rearrangement. <i>EMBO Journal</i> , 2006, 25, 1559-1568.	3.5	46
51	Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. <i>Science Advances</i> , 2021, 7, .	4.7	45
52	VP5* Rearranges when Rotavirus Uncoats. <i>Journal of Virology</i> , 2009, 83, 11372-11377.	1.5	43
53	The path to an RSV vaccine. <i>Current Opinion in Virology</i> , 2013, 3, 332-342.	2.6	43
54	Effect of Mutations in VP5* Hydrophobic Loops on Rotavirus Cell Entry. <i>Journal of Virology</i> , 2010, 84, 6200-6207.	1.5	40

#	ARTICLE	IF	CITATIONS
55	A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes. <i>Journal of Virology</i> , 2014, 88, 11802-11810.	1.5	38
56	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.	2.9	36
57	Anomalously low endemic goiter prevalence among Efe pygmies. <i>American Journal of Physical Anthropology</i> , 1989, 78, 527-531.	2.1	29
58	Cross-Linking of Rotavirus Outer Capsid Protein VP7 by Antibodies or Disulfides Inhibits Viral Entry. <i>Journal of Virology</i> , 2011, 85, 10509-10517.	1.5	24
59	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. <i>Nature Communications</i> , 2021, 12, 7105.	5.8	22
60	Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models. <i>Toxicologic Pathology</i> , 2022, 50, 280-293.	0.9	21
61	<i>Saccharomyces cerevisiae</i> -derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease. <i>Vaccine</i> , 2017, 35, 3615-3620.	1.7	18
62	Human RNA Polymerase I-Driven Reverse Genetics for Influenza A Virus in Canine Cells. <i>Journal of Virology</i> , 2010, 84, 3721-3725.	1.5	15
63	Bringing influenza vaccines into the 21st century. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 600-604.	1.4	14
64	H1N1: Can a Pandemic Cycle Be Broken?. <i>Science Translational Medicine</i> , 2010, 2, 24ps14.	5.8	6
65	Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. <i>Journal of Molecular Cell Biology</i> , 2011, 3, 144-146.	1.5	4
66	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
67	Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease. <i>Vaccines</i> , 2021, 9, 860.	2.1	2
68	Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. <i>Vaccines</i> , 2022, 10, 1074.	2.1	2
69	Building an insurance against modern pandemics. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 126-30.	2.3	1